N-(40-acetyl-22-methyl-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3(50),4,6(49),8(48),9,11,14(47),15,17(46),29,31,33(45),34,36,38-pentadecaen-19-yl)-2-aminopropanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-(40-acetyl-22-methyl-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3(50),4,6(49),8(48),9,11,14(47),15,17(46),29,31,33(45),34,36,38-pentadecaen-19-yl)-2-aminopropanamide
• 化学式: C₄₉H₄₇N₇O₉
• 分子量: 877.9
• InChiKey: KWGKGYGJGTXABK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  65
• 可旋转键数：
  3
• 环数：
  10.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  236
• 氢给体数：
  7
• 氢受体数：
  10

文献信息

• VANCOMYCIN DERIVATIVES
  申请人：Seachald Pharmaceuticals, Inc.

  公开号：US20140171357A1

  公开（公告）日：2014-06-19

  The invention features vancomycin class compounds modified to be suitable for oral delivery or to possess increased antimicrobial potency, formulations for the oral administration of vancomycin class compounds, and synthetic methods for making vancomycin class compounds.